Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

Condition:   Nasal Polyposis
Interventions:   Biological: Benralizumab 30 mg SC + Mometasone Furoate;   Biological: Matching placebo SC + Mometasone Furoate
Sponsor:   AstraZeneca
Not yet recruiting

http://ift.tt/2B9UelS